Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

Kotani, Daisuke; Oki, Eiji; Nakamura, Yoshiaki; Yukami, Hiroki; Mishima, Saori; Bando, Hideaki; Shirasu, Hiromichi; Yamazaki, Kentaro; Watanabe, Jun; Kotaka, Masahito; Hirata, Keiji; Akazawa, Naoya; Kataoka, Kozo; Sharma, Shruti; N. Aushev, Vasily; Aleshin, Alexey; Misumi, Toshihiro; Taniguchi, Hiroya; Takemasa, Ichiro; Kato, Takeshi; Mori, Masaki; Yoshino, Takayuki

doi:10.1038/s41591-022-02115-4

Public

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

Published in Nature Medicine • Jan 1, 2023

Authors:

Daisuke Kotani

Eiji Oki

Yoshiaki Nakamura

Abstract

Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making. We report results from GALAXY, which is an obse...

Subject

Medicine

Internal medicine

Colorectal cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!